
DBVT Stock Forecast & Price Target
DBVT Analyst Ratings
Bulls say
DBV Technologies is a late clinical-stage biopharmaceutical company that is developing a novel technology platform called Viaskin, which is a skin patch that delivers biologically active compounds to the immune system. The company's lead product candidate, Viaskin Peanut, is in development for the treatment of peanut-allergic patients and has shown positive results in clinical trials. The company also has other food allergy programs in earlier stages of development. With their innovative EPIT approach and positive clinical data, DBV Technologies has the potential to change the immunotherapy landscape and become a leader in the treatment of food allergies. However, potential risks include delays in BLA submissions and setbacks in clinical, regulatory, or commercial plans. Overall, given the company's strong financial position and potential for market leadership in the food allergy space, a positive outlook is warranted.
Bears say
DBV Technologies is facing potential headwinds due to its focus on a single product candidate, Viaskin Peanut, and its reliance on the success of this product for its future growth. While the company's anticipated YE26 net cash position and continued execution on commercialization efforts are strengths, high expectations for peak US sales of ~$3B may not be realistic, and competition from established players in the allergy space may hinder market share. As a result, our $51 price target, based on a sum-of-the-parts analysis, reflects a cautious outlook on DBV's stock performance.
This aggregate rating is based on analysts' research of DBV Technologies SA Sponsored ADR and is not a guaranteed prediction by Public.com or investment advice.
DBVT Analyst Forecast & Price Prediction
Start investing in DBVT
Order type
Buy in
Order amount
Est. shares
0 shares